FTPP
Adipotide (also known as FTPP or prohibitin-targeting peptide) is a peptidomimetic that targets blood vessels supplying white adipose tissue, causing fat cell apoptosis and weight loss in obese monkeys; renal tubule effects were also observed.
Regulatory status (as of Sept 2026)
Not FDA-approved. Not among the peptides named in the 2026 PCAC actions.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote6 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Adipotide (FTPP) is a compound studied only in animals and lab experiments so far. Adipotide (also known as FTPP or prohibitin-targeting peptide) is a peptidomimetic that targets blood vessels supplying white adipose tissue, causing fat cell apoptosis and weight loss in obese monkeys; renal tubule effects were also observed.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsObese Old World monkeys (rhesus and other species), daily subcutaneous dosing over about 4 weeks at 'experimentally determined optimal doses' (Barnhart 2011). The exact mg/kg is in the full text. No human data are available from PubMed.Community-reportedCommunity-reported: 0.5–1.0 mg/kg (research dosing), subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is designed to find the blood vessels that feed fat tissue and kill those vessel cells; this was studied in obese monkeys. Proposed mechanism, from a study in obese monkeys (Barnhart 2011): a targeting sequence (CKGGRAKDC) that binds prohibitin on blood vessels in white fat, fused to a pro-apoptotic peptide (D(KLAKLAK)2) that disrupts mitochondrial membranes. In obese monkeys it induced targeted apoptosis in white-fat blood vessels, with weight loss and improved insulin resistance, and caused predictable, reversible changes in kidney proximal-tubule function.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedCommonly reported doses range from 0.5 to 1.0 mg/kg (research dosing) — subcutaneous injection. This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
Adipotide (FTPP - Fat-Targeted Proapoptotic Peptide) is a chimeric peptidomimetic designed to induce targeted fat loss by attacking the blood vessels that supply white adipose tissue. Developed at MD Anderson Cancer Center and the University of Texas, it represents a fundamentally different approach to obesity treatment — rather than suppressing appetite or blocking fat absorption, it physically eliminates fat tissue by cutting off its blood supply. In a 2011 study in obese monkeys (Barnhart et al.), Adipotide treatment over 4 weeks led to weight loss and reduced white adipose tissue, with improved insulin resistance. However, reversible kidney toxicity was observed, and the compound has not progressed to human trials.
CKGGRAKDC-GG-D(KLAKLAK)2 (chimeric peptidomimetic)
Molecular Weight: ~2,500 Da
Structure Details: Chimeric peptidomimetic consisting of a cyclic targeting peptide (CKGGRAKDC) linked via a glycine-glycine spacer to a D-amino acid pro-apoptotic sequence. The D-amino acid portion resists enzymatic degradation.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Adipotide (FTPP) | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| 5-Amino-1MQ | Unknown | Oral | Preclinical (animal) |
| AOD-9604 | No published PK data found | Subcutaneous injection | Discontinued |
| Dulaglutide | ~5 days | Subcutaneous injection | FDA-approved |
| Exenatide | 2.4 hours (immediate-release) | Subcutaneous injection | FDA-approved |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Metabolic category. View All Metabolic Peptides
Research
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.